Related Experiment Video
Updated: Apr 13, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Balanced hydroxyethyl starch solution and hyperglycaemia in non diabetics - a prospective, randomized and controlled
Soumya Sankar Nath1, Sundeep T Pawar, Farrukh Ansari
1Department of Anaesthesiology, Sahara Hospital, Viraj Khand, Gomtinagar, Lucknow, India. soumynath2185@gmail.com.
Anaesthesiology Intensive Therapy
|May 6, 2015
Summary
Hydroxyethyl starch (HES) solutions did not significantly alter blood glucose levels in patients undergoing lower limb surgery. This study found no increase in blood glucose when HES was administered compared to saline, suggesting its safety for glucose regulation.
Area of Science:
- Anesthesiology
- Pharmacology
- Critical Care Medicine
Background:
- Limited research exists on the impact of hydroxyethyl starch (HES) solutions on blood glucose levels.
- HES is commonly used as a fluid resuscitation agent in surgical settings.
Purpose of the Study:
- To compare the effects of hydroxyethyl starch (HES) versus 0.9% saline on blood glucose levels.
- To evaluate the safety of HES regarding glycemic control in patients undergoing lower limb surgery under neuraxial block.
Main Methods:
- A randomized trial involving 160 non-diabetic patients (ASA I-II, aged 18-65) undergoing lower limb surgery.
- Patients received either HES (Tetraspan™) or 0.9% saline for preloading and maintenance fluid therapy.
- Blood glucose levels were measured at baseline and at 2, 4, and 6 hours post-infusion.
Main Results:
- No statistically significant differences in blood glucose levels were observed between the HES group and the saline group at any time point.
- Fasting/baseline glucose levels, as well as increases at 2, 4, and 6 hours, were comparable between both groups.
- The administration of a balanced HES solution did not lead to hyperglycemia.
Conclusions:
- Balanced hydroxyethyl starch (HES) solutions administered intravenously do not adversely affect blood glucose concentrations.
- HES can be safely used in patients undergoing surgery without causing significant glycemic alterations compared to 0.9% saline.
More Related Videos
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
905
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
905
01:06Oral Hypoglycemic Agents: Glinides
987
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
987
01:15Diabetes: Symptoms, Diagnosis, and Complications
2.9K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.9K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
984
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
984
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K